GENE ONLINE|News &
Opinion
Blog

NASH
Trials & Approvals NASHMASH
Resmetirom Offers Hope for MASH Patients: Positive Phase 3 Results for Liver Fibrosis
2024-02-15
Biotech NASH
New Technology and Nomenclature to Lead the Transformation of Fatty Liver Disease Diagnosis
2024-01-24
COVID-19 COVID-19 Treatment
The Absence of Long COVID Treatment Plans Has Become a New Business Opportunity for Medium-sized Pharmas
2022-03-30
R&D NASH
Gannex Pharma Announces New Dual Targeting Drug for NASH
2022-01-05
China Series C Funding
China’s Metabolic Drugmaker Scores $70M Series C to Accelerate Drug Trials
2021-10-13
LATEST
How FIRM is Shaping Regenerative Medicine in Japan
2024-12-09
AI, Smart Tech, and ICT to Unite the Global Biotech and Healthcare Industries in 2025
2024-12-06
Core8 Group to Establish Vietnam’s First Comprehensive Biotechnology Incubator
2024-12-05
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
2024-12-05
Ipsen Bets $600M on Biomunex’s First-in-Class T-Cell Engager BMX-502
2024-12-03
Gilead Strikes Again: $415M Bet on ADCs with Tubulis Deal
2024-12-03
FDA Investigates Reports of Blood Cancer Cases Linked to Gene Therapy
2024-12-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top